文献速递白血病

有效反应指标:利用时间序列基因表达谱预测儿童急性淋巴细胞白血病复发的新工具

Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling.
PubMed 文献 · Br J Haematol · 2018-01-01

研究假设缓解诱导治疗期间骨髓样本的时间序列基因表达谱可测量治疗反应并预测复发,据此计算从诊断到缓解诱导第8天的时间序列变化即有效反应指标(ERM-D8),在131例训练集和79例独立验证集中检验其对复发的预测能力,并与NCI标准、遗传学和微小残留病(MRD)等现行风险分层方法比较。

要点

  • ERM-D8在独立盲法测试集中预测复发,不良组5年累积复发率38.1% vs 良好组10.6%(P=2.5×10-3)。
  • 校正NCI标准、遗传学、第8天外周血反应和第33天MRD后,ERM-D8仍可预测复发(P=0.05;HR 4.09,95%CI 1.03-16.23)。
  • ERM-D8改善了良好遗传学亚组(P=0.01)和第33天MRD阳性患者(P=1.7×10-3)的风险分层。

核心结论

  • 基于缓解诱导治疗8天后时间序列基因表达谱的新指标ERM-D8可独立预测复发,即使校正NCI风险、遗传学、第8天外周血反应和MRD后仍具预测价值。

研究设计与样本

  • 研究计算从诊断到缓解诱导第8天的时间序列基因表达谱变化即ERM-D8,在131例患者训练集上训练,并在79例独立验证集上验证。

主要发现

  • 在独立盲法测试集中,ERM-D8不良组较良好组复发风险增加逾3倍(5年累积复发率38.1% vs 10.6%;P=2.5×10-3)。
  • 校正NCI标准、遗传学、第8天外周血反应和第33天MRD后,ERM-D8仍可预测复发(P=0.05;风险比4.09,95%CI 1.03-16.23)。
  • ERM-D8改善了良好遗传学亚组(P=0.01)和第33天MRD阳性患者(P=1.7×10-3)的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate risk assignment in childhood acute lymphoblastic leukaemia is essential to avoid under- or over-treatment. We hypothesized that time-series gene expression profiles (GEPs) of bone marrow samples during remission-induction therapy can measure the response and be used for relapse prediction. We computed the time-series changes from diagnosis to Day 8 of remission-induction, termed Effective Response Metric (ERM-D8) and tested its ability to predict relapse against contemporary risk assignment methods, including National Cancer Institutes (NCI) criteria, genetics and minimal residual disease (MRD). ERM-D8 was trained on a set of 131 patients and validated on an independent set of 79 patients. In the independent blinded test set, unfavourable ERM-D8 patients had >3-fold increased risk of relapse compared to favourable ERM-D8 (5-year cumulative incidence of relapse 38·1% vs. 10·6%; P = 2·5 × 10-3 ). ERM-D8 remained predictive of relapse [P = 0·05; Hazard ratio 4·09, 95% confidence interval (CI) 1·03-16·23] after adjusting for NCI criteria, genetics, Day 8 peripheral response and Day 33 MRD. ERM-D8 improved risk stratification in favourable genetics subgroups (P = 0·01) and Day 33 MRD positive patients (P = 1·7 × 10-3 ). We conclude that our novel metric - ERM-D8 - based on time-series GEP after 8 days of remission-induction therapy can independently predict relapse even after adjusting for NCI risk, genetics, Day 8 peripheral blood response and MRD.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Yeoh AE, Li Z, Dong D, et al. Effective Response Metric: a novel tool to predict relapse in childhood acute lymphoblastic leukaemia using time-series gene expression profiling. Br J Haematol. 2018. PMID: 29808917. doi:10.1111/bjh.15252

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。